ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology, Inc. (ZIOP) Stock Overview
Explore ZIOPHARM Oncology, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
208.1M
P/E Ratio
32.03
EPS (TTM)
$-0.42
ROE
24.62%
ZIOP Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of ZIOPHARM Oncology, Inc. (ZIOP) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $2.52.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 32.03 and a market capitalization of 208.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.